Clinuvel PharmaceuticalsASX:CUV -0.60%81 Gross Margin % is 94.20% as of Dec. 2025, which is 17% above its 10-year median of 80.58. GuruFocus rates ASX:CUV with a GF Score™ of 81/100 and a GF Value™ of A$17.71 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 736 Biotechnology companies, Clinuvel Pharmaceuticals ranks better than 74.73% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Clinuvel Pharmaceuticals had a gross margin of 94.20% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Clinuvel Pharmaceuticals Gross Margin % Related Terms
Clinuvel Pharmaceuticals Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CUV vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Clinuvel Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clinuvel Pharmaceuticals Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Clinuvel Pharmaceuticals's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Clinuvel Pharmaceuticals (ASX:CUV) has a Gross Margin % of 94.20% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Clinuvel Pharmaceuticals and its competitors. This is 17% above median its historical median of 80.58. Over the past decade, Clinuvel Pharmaceuticals' Gross Margin % has ranged from 39.88 to 90.16. According to the industry distribution chart, Clinuvel Pharmaceuticals ranks #186 out of 736 companies in the Biotechnology industry, placing it in the top 25.3%.
Is Clinuvel Pharmaceuticals' Gross Margin % too high?
Clinuvel Pharmaceuticals' current Gross Margin % of 94.20% is 17% above median its 10-year median of 80.58. Over the past 10 years, this metric has ranged from a low of 39.88 to a high of 90.16. The Biotechnology industry median Gross Margin % is 60.91. Clinuvel Pharmaceuticals' value of 94.20% is 54.7% above this industry median. Based on the distribution chart, Clinuvel Pharmaceuticals ranks #186 out of 736 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Clinuvel Pharmaceuticals has a GF Score™ of 81/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Clinuvel Pharmaceuticals' Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Clinuvel Pharmaceuticals ranks #186 out of 736 companies for Gross Margin %. This puts Clinuvel Pharmaceuticals in the upper half of its industry. The industry median Gross Margin % is 60.91. Clinuvel Pharmaceuticals' value of 94.20% is 54.7% above this benchmark. Historically, Clinuvel Pharmaceuticals' own Gross Margin % has ranged from 39.88 to 90.16 over the past decade. While the company's 10-year median is 80.58 vs. the industry median of 60.91, Clinuvel Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 736 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Clinuvel Pharmaceuticals's current Gross Margin % of 94.20% is 54.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Clinuvel Pharmaceuticals and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clinuvel Pharmaceuticals's current Gross Margin % is 94.20%, which is 17% above median its own 10-year median of 80.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinuvel Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Clinuvel Pharmaceuticals (ASX:CUV) is currently considered Significantly Undervalued. The stock's GF Value™ is A$17.71, compared to a current price of A$9.99 — trading 43.6% below its estimated fair value. The current Gross Margin % is 94.20%, which is 17% above median its 10-year median of 80.58 and 54.7% above the Biotechnology industry median of 60.91. Clinuvel Pharmaceuticals' overall GF Score™ is 81/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Clinuvel Pharmaceuticals (ASX:CUV), the current Gross Margin % is 94.20% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clinuvel Pharmaceuticals (ASX:CUV) Overvalued in 2026?
Based on GuruFocus' analysis, Clinuvel Pharmaceuticals stock appears to be undervalued.
The current stock price of A$9.99 is trading 43.6% below its estimated GF Value™ of A$17.71.
GuruFocus considers Clinuvel Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for ASX:CUV:
Gross Margin %: 94.20% (17% above median its 10-year median of 80.58)
GF Value™: A$17.71 vs. price of A$9.99 (43.6% below fair value)
Industry Position: 54.7% above the Biotechnology median (#186 of 736)
No single metric tells the full story. See the ASX:CUV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.
81GF Score
Get the complete analysis for ASX:CUV
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CUV has been successfully added to your 
